Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124308 | 0.88 | CYP4F2 (0.50) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL7886929 | 0.85 | GAA (0.49) | GAAMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL31053255 | 0.85 | GAA (0.49) | GAAMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL27176902 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL19837892 | 0.84 | CYP4F2 (0.51) | CYP4F2CYP4A11GAAHPGDKMT2A | |
| SCHEMBL27176866 | 0.82 | CYP4F2 (0.66) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL31248058 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL901696 | 0.82 | CYP4F2 (0.53) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL28366135 | 0.81 | CYP4F2 (0.49) | CYP4F2CYP4A11GAAMEN1HPGD | |
| SCHEMBL9035569 | 0.81 | CYP4F2 (0.49) | CYP4F2CYP4A11GAAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| CN-111971288-B | Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) | 普莱鲁德疗法有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3765461-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220177481-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-06-09 | — | — | US | disclosed |
| US-20220152073-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3946352-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11214574-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3765461-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200291037-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-09-19 | — | — | US | disclosed |
| WO-2019178368-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9499497-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2922847-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Vertex Pharmaceuticals Incorporated (US) | 2015-09-30 | — | — | EP | disclosed |
| US-9073875-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-26 | — | — | US | disclosed |
| WO-2014081689-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214574-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-20220152073-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2088/4885CYP4A11 3433/4885GAA 2510/4885 |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2088/4885CYP4A11 3433/4885GAA 2510/4885 |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | CYP4F2 704/4885CYP4A11 494/4885GAA 291/4885 |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | CYP4F2 704/4885CYP4A11 494/4885GAA 291/4885 |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-20220177481-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
| US-20200291037-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP4F2 2338/4885CYP4A11 2981/4885GAA 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.